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Symptoms of chronic venous disease and
association with systemic inflammatory markers
Mohammad H. Howlader, FRCS (Eng),a and Philip D. Coleridge Smith, DM, FRCS,b London, England
Purpose: We recorded symptoms reported by patients with chronic venous disease (CVD) of the leg and correlated these
with systemic inflammatory markers.
Methods: This was an observational study in a cohort of 132 adult patients with CVD attending the vascular clinic of a
teaching hospital. Patients were excluded in whom recent surgery, illness, or concomitant medication may have influenced
measurements of systemic inflammatory mediators. Patients with CEAP clinical stages C2 to C5 only were considered for
inclusion in the study. CEAP clinical stage was established for each patient, and duplex ultrasound scanning was used to
assess extent of venous disease in the lower limbs. Blood was taken from a foot vein, and the following inflammatory
mediators were measured with enzyme-linked immunosorbent assay: von Willebrand factor, intercellular adhesion
molecule 1, vascular cell adhesion molecule 1, soluble (s)E-selectin, sP-selectin, L-selectin, VEGF, and cytokines
interleukin (IL)–1, IL-1, IL-6, and tumor necrosis factor–. Symptoms were recorded by patients using a visual analog
scale (VAS) for the symptoms of pain, cramps, heaviness, paresthesia, and feeling of swelling.
Results: The greatest VAS symptom scores were observed in the less severe disease stages: C2 median pain score, 2.8 units
(interquartile range [IQR], 0.1-5); C3, 4.5 (IQR, 3.4-5.5), C4, 0.5 (IQR, 0-3.0); C5, 0 (IQR, 0-4). Symptom scores were
similar in patients with primary and recurrent venous disease after previous surgery and in patients with superficial venous
reflux and deep venous reflux. No correlation was found between the measurements of inflammatory mediators and the
symptoms assessed with the VAS.
Conclusion: We found no correlation between symptoms reported by patients and the internationally agreed clinical stages
of venous disease of C2 to C5. Neither was there any correlation between levels of inflammatory mediators and patient
symptoms. Symptoms reported by patients with CVD cannot be explained by anatomic distribution of venous disease in
the lower limb veins or by the systemic inflammatory response in venous disease. (J Vasc Surg 2003;38:950-4.)
Chronic venous disease (CVD) of the lower limb,
including varicose veins and leg ulceration, is a common
problem in many countries. A recent epidemiologic study
found that varicose veins develop in 40% of men and 32% of
women, with skin changes attributable to venous disease in
9% of men and 7% of women, a risk that increases with age.1
Varicose veins produce a wide range of symptoms.2 A poor
relationship is found between extent of venous reflux on
duplex ultrasound (US) scans and symptoms reported by
patients.3 In the Edinburgh Vein Study the level of agree-
ment between the presence of symptoms and trunk varices
was too low to be of clinical value.2 A more objective view
might be taken with knowledge of the mechanisms result-
ing in venous disease. We have previously suggested that
leukocytes, which accumulate in the microcirculation dur-
ing venous hypertension, are activated, releasing toxic me-
tabolites, proteolytic enzymes, and free radicals.4 Inflam-
matory processes are present in the walls of varicose veins.5
Therefore a possible explanation for the variability of symp-
toms associated with varicose veins may be that the systemic
inflammatory response determines the severity of symp-
toms reported by patients with CVD.
We investigated the symptoms reported by patients
with CVD of several CEAP6 stages and correlated those
symptoms with inflammatory markers.
MATERIAL AND METHODS
Approval for the study was obtained from University
College London Medical School Committee for Medical
Ethics. Patients considered for entry in the study were those
attending The Middlesex Hospital outpatient clinic for
management of venous disease. Those suitable for inclu-
sion in the study were canvassed with a letter of explanation
of the nature of the study. Patients older than 18 years with
CEAP clinical class C2 (varicose veins), C3 (edema), C4
(skin changes), and C5 (healed ulcer) disease were consid-
ered. We included patients with unilateral and bilateral
venous disease without distinction, because patients with
clinical venous disease in one limb commonly have a venous
disorder in the other limb,7 and defining unilateral venous
disease therefore is a problem. Patients with open ulcer
(C6) were not included, because of possible inflammation
and infection associated with the ulcer that might influence
the inflammatory markers measured. Care was taken to
exclude patients with any other illness or recent drug or
surgical treatment that may have resulted in elevated in-
flammatory markers. Exclusion criteria, which were strin-
gent to avert the influence of confounding factors on the
inflammatory markers, are listed in Table I. Of 192 pa-
tients, only 132 patients were selected for inclusion in the
final study.
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Patients who fulfilled the entry criteria and gave in-
formed written consent were studied further. All patients
were assessed clinically by a vascular surgeon skilled in
management of venous diseases, to assign the appropriate
clinical grade of the CEAP classification. A medical history
was taken, including details of any previous venous surgery
and clinical examination performed, including assessment
of the lower limbs. The venous system of the lower limb was
evaluated by an experienced vascular technologist with
duplex US scanning, to establish the extent of venous
reflux. The number of patients studied, their age and sex
distribution, duplex US scanning findings in various groups
of CEAP are summarized in Table II.
The study was conducted in an environmental chamber
at 22°C. All patients were acclimatized for 10 to 20 minutes
while lying supine before the start of the experimental
protocol, to minimize venous pressure in the leg. A 23-
gauge cannula (Venisystems Butterfly; Abbott, Sligo, Ire-
land) was placed in the distal long saphenous vein or dorsal
foot vein of the more severely affected leg, and 8 mL of
blood was collected into two tubes containing ethylenedi-
amenetetraacetic acid (EDTA) (Vacutainer, BP No. 37-
38241; Becton Dickinson Vacutainer Systems Europe,
Grenoble, France). A complete blood cell count, including
differential leukocyte count, was performed on all blood
samples. Plasma from the samples was separated with cen-
trifugation at 20,000 rpm for 10 minutes at 4°C within 1
hour of collection and was promptly frozen at 84°C
before analysis with enzyme-linked immunosorbent assay
(ELISA). Intracellular adhesion molecule 1 and vascular
adhesion molecule 1 were assayed with a commercially
available kit (Diaclone; Cedex, Besanc¸on, France), and
soluble (s) E-selectin, sP-selectin, L-selectin, vascular en-
dothelial growth factor, and cytokines interleukin (IL)–1,
IL-1, IL-6, and tumor necrosis factor– (TNF-) were
measured with commercially available ELISA kits (R & D
Systems Europe, Oxford, UK). von Willebrand factor was
measured with a kit manufactured by Shield Diagnostics,
Aberdeen, Scotland. Highly sensitive kits were used to
measure IL-1, TNF-, and IL-6.
The symptoms of venous insufficiency, including pain,
cramps, heaviness, paresthesia, and a feeling of swelling
(edema) were assessed by asking the patient to mark on a
visual analog scale (VAS) of 0 to 10 units, where severe
symptoms was 10 and absence of symptoms was 0.
Statistical analysis. The Statistical Package for the
Social Sciences (SPSS, Chicago, Ill) was used to analyze the
data, with nonparametric tests for paired and unpaired data
(Wilcoxon matched pairs signed rank test and Mann-
Whitney U test). The difference between median and 95%
confidence interval was calculated with the Wilcoxon
method. All results are described as median and interquar-
tile range.
RESULTS
Subjects in each clinical group were of similar age and
sex distribution. The number of patients with superficial
and deep venous incompetence in each study group is
summarized in Table II. One hundred thirty-two patients
(60 men, 72 women; median age, 53 years [range, 45-64
years]) with CVD were included. Only 3 patients had a
history of thrombosis (thrombosis within a year excluded
from the study), detected at duplex ultrasound scanning.
Patients with more severe clinical stages of venous
disease reported fewer symptoms than did patients with
uncomplicated varicose veins. For example, scores for the
symptoms of pain and heaviness in patients with C2 and C3
clinical stages greatly exceeded scores for patients with C4
and C5 disease. Severity of symptoms reported was not
influenced by anatomic distribution of venous reflux, cate-
gorized as superficial venous reflux or deep venous reflux,
or by a history of varicose vein surgery (Table III).
The association of symptoms with inflammatory mark-
ers was also investigated. This is presented in two ways in
Table IV. The VAS for each patient was examined, and if
the score was 0.5 units or less, the patient was scored as
asymptomatic for this symptom. Patients were then divided
into an asymptomatic and a symptomatic group. Results of
ELISA for each parameter were compared between the two
groups. In general, few differences were found between
patients when divided in this way. Plasma VEGF levels were
higher in patients reporting swelling (edema) than in pa-
tients without this symptom. However, in view of the large
number of comparisons made, this may well have resulted
by chance. The Pearson correlation coefficient (r) was also
calculated for each paired symptom and inflammatory me-
diator. For most biologic markers the value was low, con-
firming the poor correlation between symptoms and bio-
logic markers. Only a weak association with correlation
coefficient of 0.2 was found for VEGF and the symptom of
edema (swelling).
For the remaining parameters measured, including in-
tracellular adhesion molecule 1, E-selectin, sP-selectin, cy-
Table I. Exclusion criteria
History of alcohol or drug abuse
Diabetes mellitus
Connective tissue disorders, including rheumatoid arthritis
Blood disorders
Arterial disease (ankle-brachial index 0.9).
Infection within previous 6 weeks
Concomitant acute or chronic disease (particularly, inflammatory
or infectious disease) that may interfere with results
Active ulcer (C6)
Recent deep venous thrombosis (within 1 y),
Recent superficial venous thrombosis (within 15 d),
Excluded medications
Nonsteroidal anti-inflammatory drugs
Corticoid agents
Salicylates
Vitamin A, Vitamin C, Vitamin E, and derivatives
Pentoxyfilline, naftidrofuryl
Any anticoagulant treatment
Any medication that alters white blood cell activity
Skin grafting
Sclerotherapy, stripping, or any surgery of varicose veins in
previous 3 mo
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tokines, and von Willebrand factor, which are not shown in
Table IV, no correlation with any symptom was found.
DISCUSSION
The authors of the Edinburgh Vein Study reported that
they could find no correlation between severity of venous
disease detected at clinical examination and duplex US
scanning and the extent of symptoms reported by pa-
tients.2,3 This was widely interpreted that symptoms of
venous disease are unrelated to venous incompetence.
However, it is clear that at least the result of venous
incompetence, venous leg ulceration, is more common
with increasing venous reflux.8 Therefore we expected to
find that objective evidence of venous disease from systemic
markers of inflammation would show an association with
clinical severity of venous disease. We were surprised to find
that patients with C2 and C3 disease reported far more
severe symptoms than patients with C4 and C5 disease
(Table III). Pain and heaviness were scored highest by
patients in the C2 and C3 groups. The finding of a high
score for feeling of swelling in the C3 group reflects the
clinical finding of edema in these patients. Edema was
probably not attributable to proximal venous obstruction
in this group, because this was detected in no patient with
C3 disease at duplex US scanning. Edema commonly ac-
companies venous disease, and is not necessarily associated
with proximal venous obstruction. The cramp score was
highest in patients with C4 disease, who reported low scores
Table II. Demographic data and duplex US scan findings in study patients
CEAP
stage
No. of
patients
Sex
distribution
(M/F)
Mean age
(y) (range)
Superficial
venous
insufficiency
Deep and
superficial
venous
insufficiency
132 60/72 53 (45-64) 90 42
C2 48 13/35 52 (44-59) 35 11
C3 18 3/15 52 (42-61) 13 4
C4 43 29/14 60 (42-66) 23 18
C5 23 15/8 53 (44-64) 13 9
Table III. Symptom scores on VAS in patients with various CEAP clinical stages
Symptom
CEAP clinical
stage Pain Heaviness Cramps Paresthesia
Edema
(swelling)
C2 2.8 (0.1-5) 2.6 (0.3-5) 2.8 (0-6.4) 0.2 (0-2.8) 0 (0-1.5)
C3 4.5 (3.4-5.5) 4.2 (0.8-5) 1.6 (0-4.5) 0 (0-1.2) 5 (3-5.9)
C2, C3 3.3 (0.6-5) 3.4 (0.2-5) 2.5 (0-5) 0 (0-2.5) 0.7 (0-5)
C4 0.5 (0-3.0) 1.4 (0-5) 4.4 (0.4-7.8) 0 (0-2.6) 1.5 (0-5)
C5 0 (0-4) 0 (0-1.3) 0 (0-6.3) 0 (0-1.8) 0 (0-2.0)
C4, C5 0 (0-3) 0.1 (0-4.8) 3 (0-6.9) 0 (0-2) 1 (0-2.4)
Difference
between
median and
95% CI*
(C2, C3 and
C4, C5)
1.8 (0.1-2.8) 0.9 (0-2) 0 (1.5-0) 0 (0-0) 0 (0.3-0.1)
SVI: C2, C3 3.4 (0.1-5) 3.5 (0.8-5) 1.5 (0-4.6) 0 (0-3.9) 1 (0-5)
DVI: C2, C3 3.1 (0.8-5.4) 2 (0.2-4.9) 4.4 (0.8-7) 0 (0-1.6) 0.5 (0-2.3)
SVI: C4, C5 0.0 (0-3.0) 0.6 (0-5) 3 (0-7) 0 (0-1.8) 1.3 (0-4)
DVI: C4, C5 0.0 (0-3) 0 (0-2.2) 3.25 (0-6.4) 0.1 (0-3.8) 0.8 (0-2.6)
Primary C2,
C3 (n  35)
3 (0.1-5) 3 (0-5) 2.4 (0-6.7) 0.02 (0-3.1) 0.10 (0-3)
Recurrent C2,
C3 (n  31)
4.5 (0.7-5) 3.5 (1.4-5) 2.75 (0-4.6) 0 (0-2.5) 1 (0-5.1)
Primary C4,
C5 (n  32)
0.2 (0-5) 0.5 (0-5) 2.0 (0-7.0) 0.1 (0-3.5) 1.5 (0-5.5)
Recurrent C4,
C5 (n  34)
0 (0-2) 0 (0-2.98) 4.3 (0-6.5) 0 (0-5) 0.2 (0-2.5)
Data expressed as median (interquartile range).
VAS, Visual analog scale in units for measurement of symptoms score on a scale of 0-10 units; SVI, superficial venous incompetence; DVI, deep venous
incompetence.
*Difference between median and 95% CI for differences between medians were calculated with the Wilcoxon method.
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for pain and heaviness. Patients with healed venous ulcers
(C5) had few symptoms. We had expected the more severe
clinical stages to be associated with higher symptom scores.
Patients with the more severe stages of venous disease have
peripheral neuropathy affecting sensory nerve fibers,9
which may result in less pain. Although the scores were
recorded objectively, the individual experience of patients
with the same clinical stage varies widely, and perception of
symptoms is extremely subjective. Patients with varicose
veins (C2) may find the symptoms from these troublesome
because they dislike the appearance of varices. They may
also consider that they will be more likely to receive treat-
ment if their symptoms are more severe. Patients with skin
changes before ulceration occurs (C4) may be grateful that
the symptoms are no worse. Patients with healed venous
ulcers (C5) may compare their present situation with the
symptoms when the ulcer was open. Because venous ulcer-
ation may be associated with severe pain,10 they may find a
healed ulcer easy to live with. The measurement of symp-
toms in this way is variable, and depends on the context in
which the patient views the severity of symptoms. We
acknowledge that arterial ulcers of the lower limb are
usually painful and that assessment of the peripheral arteries
is appropriate in such cases; however, this is not the subject
of this article.
In analyzing the data from this investigation, we used a
crude anatomic distinction for location of venous disease,
either affecting the superficial veins alone or including the
deep veins as well. This classification is more simplistic than
other methods,3 but we come to the same conclusion, that
is, that symptoms appear unrelated to the veins affected by
venous disease. We also assessed the contribution of previ-
ous superficial venous surgery, which again had no effect on
the symptoms reported by our patients.
Our hypothesis that patient symptoms may be related
to some aspect of the systemic inflammatory response to
Table IV. Association of symptoms (from VAS) with various biologic markers in patients with CVD
Symptoms
Severity
distribution in
VAS
Asymptomatic vs
symptomatic
group
Age (y)
Parameters
Asymptomatic vs
symptomatic*
r†Mean Range Mean Range
Pain 0 (0-0.1) 63 in each group 56 (45-68) L-selectin 799 (663-1004) 0.1
vs vs vs
5 (3.3-5.5) 53 (46-62) 944 (771-1105)
sVCAM-1 1189 (926-1453) 0.1
vs
1289 (1045-1569)
Heaviness 0 (0-0.2) 66 in each group 57 (48-69) L-selectin 820 (663-1055) 0.1
vs vs vs
5 (3.5-6.4) 52 (42-59) 901 (732-1088)
VEGF 61 (35-111) 0.01
vs
78 (35-126)
Cramps 0 (0-0.5) 66 in each group 53 (41-61) VEGF 57 (34-116) 0.1
vs vs vs
6.5 (4.4-8.5) 54 (47-65) 72 (38-123)
Paresthesiae 0 (0-0)
vs
3.1 (0.7-5)
71 in
asymptomatic
group; 61 in
symptomatic
group
54 (47-64)
vs
53 (43-64)
VEGF 79 (43-124)
vs
51 (31-111)
0.12
L-selectin 790 (658-949) 0.11
vs
982 (798-1310)
Edema
(swelling)
0 (0-0)
vs
5 (2.5-6)
70 in
asymptomatic
group; 64 in
symptomatic
group
55 (44-66)
vs
53 (46-63)
VEGF 54 (31-104)
vs
85 (40-147)
0.2
Difference
between
median:
20 95%
CI, 5-
44‡
VAS, Visual analog scale; CVD, chronic venous disease; sVCAM-1, vascular adhesion molecule 1; VEGF, vascular endothelial growth factor.
Data separated to show symptomatic and asymptomatic groups.
*Associated median biologic marker values for the two groups.
†Pearson correlation coefficient between symptom VAS scores and levels of biologic markers of inflammation.
‡Difference between median and 95% CI for differences between medians were calculated with the Wilcoxon method.
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venous disease is based on previous publications that show
a relationship between severity of venous disease and extent
of the elevation of markers of inflammation.11,12 These
factors have not been investigated as the source of symp-
toms in previous studies. The low values for the correlation
coefficients demonstrate that none of the factors investi-
gated here correlates well with any of the symptoms mea-
sured with the VAS. We conclude that the extent of the
systemic inflammatory response, as indicated by the bio-
logic markers, does not explain the variability in symptoms
reported by patients with venous disease.
It is clear from several studies that the clinical syndrome
resulting from venous incompetence in the lower limb
worsens with increasing severity of venous reflux. The
internationally agreed CEAP classification of clinical find-
ings in venous disease is clear about the features of ascend-
ing severity of the clinical syndrome.6 Patients with skin
changes attributable to venous disease have elevated sys-
temic markers of inflammation. However, measurement of
clinical severity stage, venous incompetence, or inflamma-
tory markers yields no evidence about severity of symptoms
that patients report, at least in patients with C2 to C5
clinical stage. The most likely explanation for lack of corre-
lation is that the assessment of symptoms is too simplistic
and prone to influence from a wide range of confounding
factors. When assessing which patients may be suitable for
surgical treatment of superficial venous reflux, those with
objective signs such as ulceration, trophic skin changes, or
edema should have higher priority than those without these
changes. However, many patients with uncomplicated var-
icose veins report significant aching and other symptoms,
which cannot be verified with objective measurement. We
have not been able to establish the source of these symp-
toms, and none of the measurements we made show any
correlation with symptom severity, and levels of inflamma-
tory mediators cannot help in determining which patients
have the most severe symptoms. We continue to rely on
clinical assessment of symptoms and their influence on
lifestyle to allocate treatment.
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